Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Total Liabilities: 2014-2024

Historic Total Liabilities for KalVista Pharmaceuticals (KALV) over the last 6 years, with Dec 2024 value amounting to $130.5 million.

  • KalVista Pharmaceuticals' Total Liabilities was N/A to $130.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $130.5 million, marking a year-over-year change of. This contributed to the annual value of $28.8 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q4 2024, KalVista Pharmaceuticals' Total Liabilities is $130.5 million, which was up 386.07% from $26.8 million recorded in Q4 2024.
  • In the past 5 years, KalVista Pharmaceuticals' Total Liabilities registered a high of $130.5 million during Q4 2024, and its lowest value of $7.6 million during Q1 2021.
  • Its 2-year average for Total Liabilities is $40.6 million, with a median of $26.8 million in 2024.
  • In the last 5 years, KalVista Pharmaceuticals' Total Liabilities crashed by 58.97% in 2020 and then soared by 30.49% in 2024.
  • Over the past 4 years, KalVista Pharmaceuticals' Total Liabilities (Quarterly) stood at $10.5 million in 2020, then crashed by 42.06% to $7.6 million in 2021, then reached $24.3 million in 2023, then increased by 10.46% to $130.5 million in 2024.
  • Its last three reported values are $130.5 million in Q4 2024, $26.8 million for Q4 2024, and $27.4 million during Q3 2024.